Milatuzumab
by Michelle Spektor
Published: Oct 4, 2010 10:36 pm
Published: Oct 4, 2010 10:36 pm
| Brand Name: | |
| Generic Name: | milatuzumab |
| Code Name: | |
| Company: | Immunomedics, Inc. |
| FDA Clinical Phase: | 1/2 |
Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials, it is currently being investigated as a treatment of multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia.
Clinical Trials:
For a list of clinical trials studying milatuzumab for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for milatuzumab: http://www.immunomedics.com/5clinical/Milatuzumab.html
Related Articles:
- Getting To Know: TNB-383B
- Getting To Know: Tiragolumab
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Lather, Rinse, Repeat: Will It Work With BCMA-Targeted Therapies For Multiple Myeloma?
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients